HKD37.18
2.26% today
Hong Kong, Sep 03, 10:09 am CET
ISIN
KYG549581067
Symbol
3692
Index

Hansoh Pharmaceutical Group Company Stock price

HKD36.36
+1.34 3.83% 1M
+18.50 103.58% 6M
+19.08 110.42% YTD
+16.38 81.98% 1Y
+22.30 158.61% 3Y
+0.41 1.14% 5Y
+16.86 86.46% 10Y
+16.86 86.46% 20Y
Hong Kong, Closing price Tue, Sep 02 2025
-0.14 0.38%
ISIN
KYG549581067
Symbol
3692
Index
Industry

Key metrics

Basic
Market capitalization
HKD221.0b
Enterprise Value
HKD191.5b
Net debt
positive
Cash
HKD29.7b
Shares outstanding
5.9b
Valuation (TTM | estimate)
P/E
41.3 | 39.1
P/S
15.3 | 13.7
EV/Sales
13.3 | 11.8
EV/FCF
-
P/B
6.5
Dividends
DPS
HKD0.37
Yield 1Y | 5Y
1.0% | 1.0%
Growth 1Y | 5Y
6.9% | -
Payout 1Y | 3Y
45.9% | 44.2%
Increased
2 Years
Financials (TTM | estimate)
Revenue
HKD14.4b | HKD16.2b
EBITDA
- | HKD5.4b
EBIT
HKD5.6b | HKD5.1b
Net Income
HKD5.2b | HKD5.5b
Free Cash Flow
-
Growth (TTM | estimate)
Revenue
9.0% | 20.8%
EBITDA
- | 12.5%
EBIT
21.0% | 17.1%
Net Income
1.4% | 15.6%
Free Cash Flow
-
Margin (TTM | estimate)
Gross
91.0%
EBITDA
- | 33.4%
EBIT
38.7%
Net
36.3% | 34.1%
Free Cash Flow
-
Financial Health
Equity Ratio
90.6%
Return on Equity
15.2%
ROCE
16.2%
ROIC
97.8%
Debt/Equity
0.0
More
EPS
HKD0.9
FCF per Share
-
Short interest
-
Employees
9k
Rev per Employee
HKD1.5m
Show more

Is Hansoh Pharmaceutical Group Company a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Hansoh Pharmaceutical Group Company Stock Analysis

Unlock Scores for Free

Analyst Opinions

28 Analysts have issued a Hansoh Pharmaceutical Group Company forecast:

26x Buy
93%
2x Hold
7%

Analyst Opinions

28 Analysts have issued a Hansoh Pharmaceutical Group Company forecast:

Buy
93%
Hold
7%

Financial data from Hansoh Pharmaceutical Group Company

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
14,421 14,421
9% 9%
100%
- Direct Costs 1,303 1,303
10% 10%
9%
13,118 13,118
9% 9%
91%
- Selling and Administrative Expenses 4,996 4,996
5% 5%
35%
- Research and Development Expense 3,221 3,221
25% 25%
22%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 5,576 5,576
21% 21%
39%
Net Profit 5,228 5,228
1% 1%
36%

In millions HKD.

Don't miss a Thing! We will send you all news about Hansoh Pharmaceutical Group Company directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Hansoh Pharmaceutical Group Co., Ltd. is a holding company, which engages in the research and development, production, and sale of a series of pharmaceutical products. Its products include oncology, anti-infective, anti-diabetic, gastrointestinal, and cardiovascular drugs. The company was founded by Huijuan Zhong on December 2, 2015 and is headquartered in Lianyungang, China.

Head office Cayman Islands
CEO Hui Zhong
Employees 8,989
Founded 2015
Website www.hspharm.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today